Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-PIPAC for Pancreatic Cancer Peritoneal Metastases
NCT05371223Phase 2Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in pancreatic cancer (PC), sponsored by Policlinico Gemelli. Primary endpoint: Disease Control Rate at 3.5 years. Started Mar 2022; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05371223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371223.